When dealing with organisms, which lack a non-human natural host, we can never be perfectly certain and therefore must rely on additional accumulated supportive (usually indirect) evidence. If our purified His-IFS (NADase inhibitor) is able to rescue STSS patients in future that could provide a more ethically acceptable form of direct evidence.

Conclusions We have presented further supportive evidence that NADase is important for severe invasive disease of S. pyogenes in vivo using the experimental mouse model. Furthermore, we provided useful evidence that the MLN8237 NADase is the potential target to suppress the virulence. Acknowledgements We thank Laura Leverton for critical reading of the manuscript and Hideki Matsui and Takayuki Ichikawa for technical assistance. This study was supported by Grant numbers 19590452 and LY2874455 datasheet 21790425 from the Ministry of Education, Science and Culture of the Japanese government. M. I. was supported by a grant for Research on Publicly Essential Drugs and Medical Devices, No.KHC1021 from the Japan Health Sciences Foundation. References 1. Cone LA, Woodard DR, Schlievert PM, Tomory GS: Clinical and bacteriologic

observations of a toxic shock-like syndrome due to Streptococcus pyogenes . N Engl J Med 1987, 317:146–149.PubMedCrossRef selleck chemicals llc 2. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ: The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 1993, 269:384–389.PubMedCrossRef 3. Schwartz B, Facklam RR, Breiman RF: Changing epidemiology of group A streptococcal infection in the

USA. Lancet 1990, 336:1167–1171.PubMedCrossRef 4. Stevens DL: Invasive group A streptococcal infections: the past, present and future. Pediatr Infect Dis J 1994, 13:561–566.PubMedCrossRef 5. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet Non-specific serine/threonine protein kinase fever toxin A. N Engl J Med 1989, 321:1–7.PubMedCrossRef 6. Hasegawa T, Hashikawa SN, Nakamura T, Torii K, Ohta M: Factors determining prognosis in streptococcal toxic shock-like syndrome: results of a nationwide investigation in Japan. Microbes Infect 2004, 6:1073–1077.PubMedCrossRef 7. Sumby P, Porcella SF, Madrigal AG, Barbian KD, Virtaneva K, Ricklefs SM, Sturdevant DE, Graham MR, Vuopio-Varkila J, Hoe NP, Musser JM: Evolutionary origin and emergence of a highly successful clone of serotype M1 group a Streptococcus involved multiple horizontal gene transfer events. J Infect Dis 2005, 192:771–782.PubMedCrossRef 8. Michos A, Gryllos I, Hakansson A, Srivastava A, Kokkotou E, Wessels MR: Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase. J Biol Chem 2006, 281:8216–8223.PubMedCrossRef 9.